Interestingly, a proteasomal inhibitor, marizomib, disrupts glucose and glutamine metabolism in HLRCC cells via inhibition of glycolysis and lowered expression of glutaminases, thus restricting nutrients and the cells’ antioxidant response capacity, supporting a potential use of proteasome inhibitors in HLRCC [88]. This evidence concerns the gene GLS and hereditary leiomyomatosis and renal cell cancer.